PDF herunterladen
Aktuelle Rheumatologie 2020; 45(06): 577-582
DOI: 10.1055/a-1154-8623
Original Article

Comparison of Oxidant and Antioxidant Parameters in Patients with Sjögren’s Syndrome and Healthy Subjects

Vergleich der Oxidations- und Antioxidationsparameter bei Patienten mit Sjögren-Syndrom und gesunden Probanden
İsmail Dogan
1   Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
,
Sukran Erten
1   Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
,
Ali Sahin
2   Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
,
Semra Isıkoglu
3   Biochemistry, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
,
Salim Neselioglu
3   Biochemistry, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
,
Merve Ergin
3   Biochemistry, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
,
Ozcan Erel
3   Biochemistry, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objective Oxidative stress may have an effect on the pathogenesis of diseases, including autoimmune rheumatic diseases. We aimed to investigate the serum paraoxonase activity and other oxidant/antioxidant parameters in patients with Sjögren’s syndrome (SS) and healthy controls.

Methods 85 patients with SS and 65 healthy subjects were included in the study. Groups were age and gender-matched and had no liver disease. Serum paraoxonase (PON)-1 activity, stimulated paraoxonase (SPON), PON-1 phenotypes that represent polymorphism (Q192R; QQ, QR, RR), arylesterase (ARE), total oxidant status (TOS), total antioxidant capacity (TAC), oxidative stress index (OSI), advanced oxidative protein products (AOPP), total thioles (TTL) and ischaemia-modified albumin (IMA) were measured in all study participants.

Results Statistically significant differences were found in the QQ and QR+RR phenotype of PON-1 for TAC, TOS and TTL (p<0.001) between SS and healthy groups. The other parameters were statistically insignificant.

Conclusion Antioxidant parameters were lower in SS patients compared with healthy controls. Conversely, oxidant parameters were higher. This imbalance may play a role in SS pathogenesis.

Zusammenfassung

Ziel Oxidativer Stress kann die Pathogenese von Krankheiten, einschließlich rheumatischer Autoimmunerkrankungen, beeinflussen. Wir wollten die Paraoxonase-Aktivität im Serum und andere oxidative / antioxidative Parameter bei Patienten mit Sjögren-Syndrom (SS) und gesunden Kontrollpersonen untersuchen.

Methode 85 Patienten mit SS und 65 gesunde Probanden wurden in die Studie eingeschlossen. Die Gruppen waren alters- und geschlechtsgleich und hatten keine Lebererkrankungen. Bei allen Studienteilnehmern wurden Serum-Paraoxonase (PON) 1-Aktivität, stimulierte Paraoxonase (SPON), PON 1-Phänotypen, die Polymorphismus darstellen (Q192R; QQ, QR, RR), Arylesterase (ARE), Gesamtoxidationsstatus (TOS), Gesamtantioxidationskapazität (TAC), oxidativer Stress-Index (OSI), fortgeschrittene oxidative Proteinprodukte (AOPP), Gesamtthiole (TTL) und Ischämie-modifiziertes Albumin (IMA) gemessen.

Ergebnisse Es gab statistisch signifikante Unterschiede im QQ- und QR+RR-Phänotyp von PON-1 für TAC, TOS und TTL (p<0,001) zwischen SS- und gesunden Gruppen. Die anderen Parameter waren statistisch nicht signifikant.

Schlussfolgerung Die Antioxidationsparameter waren bei SS-Patienten im Vergleich zu gesunden Kontrollen niedriger, und umgekehrt waren die Oxidationsparameter höher. Dieses Ungleichgewicht kann eine Rolle bei der SS-Pathogenese spielen.

Key words

Oxidant/antioxidant status - paraoxonase - Sjögrenʼs syndrome

Schlüsselwörter

Oxidationsmittel- - Antioxidationsmittelstatus - Paraoxonase - Sjögren-Syndrom


Publikationsverlauf

Artikel online veröffentlicht:
14. Mai 2020

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Meijer JM, Meiners PM, Vissink A. et al. Effectiveness of rituximab treatment in primary Sjögrenʼs syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-968
    CrossrefPubMedGoogle Scholar
  • 2 Yumru M, Savas HA, Kalenderoglu A. et al. Oxidative imbalance in bipolar disorder subtypes: A comparative study. Prog in Neuropsychopharmacol Biol Psychiatry 2009; 33: 1070-1074
    CrossrefPubMedGoogle Scholar
  • 3 Smallwood MJ, Nissim A, Knight AR. et al. Oxidative stress in autoimmune rheumatic diseases. Free Radic Biol Med 2018; 125: 3-14 DOI: 10.1016/j.freeradbiomed.2018.05.086.
    CrossrefPubMedGoogle Scholar
  • 4 Ceron JJ, Tecles F, Tvarijonaviciute A. Serum paraoxonase 1 (PON1) measurement: an update. BMC Vet Res 2014; Mar 25 10: 74 DOI: 10.1186/1746-6148-10-74.
    CrossrefPubMedGoogle Scholar
  • 5 Vitali CBombardieri, Johnson R. et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 544-558
    CrossrefPubMedGoogle Scholar
  • 6 Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-119
    CrossrefPubMedGoogle Scholar
  • 7 Browne RW, Koury ST, Marion S. et al. Accuracy and Biological Variation of Human Serum Paraoxonase 1 Activity and Polymorphism (Q192R) by Kinetic Enzyme Assay. Clin Chem 2007; 53: 310-317
    CrossrefPubMedGoogle Scholar
  • 8 Eckerson HW, Wyte CM, La DuBN.. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138
    PubMedGoogle Scholar
  • 9 La DuBN, Eckerson HW. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 1984; 43: 2338
    PubMedGoogle Scholar
  • 10 Szanto A, Harangi M, Seres I. et al. Decreased human paraoxonase-1 activity in patients with Sjögren’s syndrome. Intern Immunol 2010; 22: 605-609
    CrossrefPubMedGoogle Scholar
  • 11 Harma M, Harma M, Erel O. Measurement of the total antioxidant response in preeclampsia with a novel automated method. Eur J Obstet Gynecol Reprod Biol 2005; 118: 47-51
    CrossrefPubMedGoogle Scholar
  • 12 Rabus M, Demirbag R, Sezen Y. et al. Plasma and tissue oxidative stress index in patients with rheumatic and degenerative heart valve disease. Turk Kardiyol Dern Ars 2008; 36: 536-540
    PubMedGoogle Scholar
  • 13 Sarban S, Kocyigit A, Yazar M. et al. Plasma total antioxidant capacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis. Clin Biochem 2005; 38: 981-986
    CrossrefPubMedGoogle Scholar
  • 14 Keskin M, Dolar E, Dirican M. et al. Baseline and Salt-stimulated Paraoxonase and Arylesterase Activities in Patients with Chronic Liver Disease: Relation with Disease Severity. Intern Med J 2009; 39: 243-248
    CrossrefPubMedGoogle Scholar
  • 15 Erdem FH, Karatay S, Yildirim K. et al. Evaluation of serum paraoxonase and arylesterase activities in Ankylosing Spondylitis patients. Clinics 2010; 65: 175-179
    CrossrefPubMedGoogle Scholar
  • 16 Isık A, Koca SS, Ustundag B. et al. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 2007; 26: 342-348
    CrossrefPubMedGoogle Scholar
  • 17 Tanimoto N, Kumon Y, Suehiro T. et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003; 72: 2877-2885
    CrossrefPubMedGoogle Scholar
  • 18 Toker A, Kadi M, Yildirim AK. et al. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009; 27: 176-180
    CrossrefPubMedGoogle Scholar
  • 19 Delgado Alves J, Ames PR, Donohue S. et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-2694
    CrossrefPubMedGoogle Scholar
  • 20 Kiss E, Seres I, Tarr T. et al. Reduced paraoxonase 1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 83-91
    CrossrefPubMedGoogle Scholar
  • 21 Şahin A, Erten Ş, Altunoğlu A. et al. Comparison of serum oxidant and antioxidant parameters in familial Mediterranean fever patients (FMF) with attack free period. Acta Reumatol Port 2014; 39: 316-321
    PubMedGoogle Scholar
  • 22 Karakucuk S, Baskol G, Oner AO. et al. Serum paraoxonase activity is decreased in the active stage of Behçet’s disease. Br J Ophthalmol 2004; 88: 1256-1258
    CrossrefPubMedGoogle Scholar
  • 23 Dogru M, Kojima T, Simsek C. et al. Potential Role of Oxidative Stress in Ocular Surface Inflammation and Dry Eye Disease. Invest Ophthalmol Vis Sci 2018; 59: DES163-DES168 DOI: 10.1167/iovs.17-23402.
    CrossrefPubMedGoogle Scholar
  • 24 Pagano G, Castello G, Pallardó FV. Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res 2013; Feb 47: 71-73 DOI: 10.3109/10715762.2012.748904.
    CrossrefPubMedGoogle Scholar
  • 25 Strickland FM, Mau T, O'Brien M. et al. Oxidative T Cell Modifications in Lupus and Sjogrenʼs Syndrome. Lupus (Los Angel) 2017; 2: 121
    PubMedGoogle Scholar